WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its financial results for the third quarter of 2024, alongside significant corporate updates. The company marked a pivotal milestone with the initiation of its Phase 2a trial for ATI-2138, targeting moderate to severe atopic dermatitis.
Dr. Neal Walker, Interim President & CEO, emphasized the importance of this development, stating, “The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis. This milestone, combined with our robust financial position, underscores our commitment to executing a capital-efficient development strategy.”
In the realm of financial performance, Aclaris reported a net loss of $7.6 million for the quarter, a substantial improvement from a $29.3 million loss in the same period last year. Total revenue reached $4.3 million, down from $9.3 million, primarily due to fewer milestone payments compared to the prior year.
Research and development expenses were significantly reduced to $6.0 million from $23.9 million in the previous year, reflecting a decrease in costs associated with earlier clinical trials and manufacturing. General and administrative expenses also fell to $5.7 million, driven by a leaner workforce and increased forfeiture credits.
The company’s liquidity remains strong, with cash, cash equivalents, and marketable securities totaling $173.4 million as of September 30, 2024. This financial stability is expected to sustain operations into 2028, providing a solid foundation for ongoing and future initiatives.
Looking ahead, Aclaris continues to advance its ITK inhibitor programs and seeks partners for the global development of lepzacitinib, aiming to leverage its strategic position and financial health to drive innovation in autoimmune disease treatments.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.